A comparison piece published on Medical News Bulletin sets BPC-157 and TB-500 side by side, and the gap it describes is not mechanism but evidence. The article carries a disclosure that it was prepared by an advertiser rather than the publication's editorial staff, which is worth knowing before you read its framing of either compound.

Both are synthetic research peptides studied in connection with tissue repair. BPC-157 is 15 amino acids copied from a protein fragment in human gastric juice, first described in 1993 by researchers at the University of Zagreb. TB-500 is seven amino acids, sequence LKKTETQ with an acetyl group attached, matching positions 17 through 23 of thymosin beta-4, a 43-amino-acid protein found throughout the body.

The thymosin confusion

The piece is unusually clear on a point most peptide marketing blurs: FDA's briefing document states directly that TB-500 and thymosin beta-4 are different substances, and notes that many websites use the names interchangeably. The acetyl group changes charge, size and binding, so decades of thymosin beta-4 trials do not transfer to the fragment being sold under the TB-500 name.

That matters because much of the tendon and anti-inflammatory literature quoted for TB-500 is actually thymosin beta-4 work or work on the non-acetylated fragment. A 2024 laboratory study cited by FDA found TB-500 itself produced no significant wound closure in scratched fibroblast cultures, though one of its breakdown products did.

What the human record contains

As cataloged in FDA's 2026 review, BPC-157 has been given to humans in five published studies, covering ulcerative colitis, knee pain and interstitial cystitis. Only the ulcerative colitis trial was randomized and placebo-controlled, and it reported a between-group difference of 1.6 points on its disease activity index with a confidence interval that crossed zero.

FDA found no published study in which TB-500 was administered to humans at all. Its adverse event search through March 2025 returned zero reports for TB-500 and three for BPC-157: injection-site reaction, shortness of breath and skin darkening.

The compounding vote

On July 23 and 24, 2026, FDA's Pharmacy Compounding Advisory Committee voted 8-6 to recommend both peptides for the 503A Bulks List, overriding the agency's own scientists, who had opposed all seven peptides under review. The vote is advisory only and formal rulemaking has to happen before anything changes.

Bottom line

Neither peptide is FDA-approved for any use, and the World Anti-Doping Agency prohibits both, BPC-157 under S0 and TB-500 under S2.3. The honest summary is that one compound has three decades of rodent work and five small human studies behind it, and the other has a mechanistic hypothesis and no human studies at all.